Management of Hyperglycemia with Hypernatremia
Assessment and Initial Management
- Point-of-care glucose monitoring should be performed frequently (every 1-2 hours initially) to guide therapy, according to the American Diabetes Association 1
Insulin Therapy
- For severe hyperglycemia (>250 mg/dL), initiate continuous intravenous insulin infusion at 0.1 units/kg/hour, as recommended by the American College of Endocrinology 2, 3
- Target a gradual reduction in glucose of 50-75 mg/dL per hour, based on guidelines from the American Diabetes Association 3
- Once glucose levels reach 200-250 mg/dL, reduce insulin infusion rate and add dextrose-containing fluids to prevent hypoglycemia while continuing to correct hypernatremia, as suggested by the European Association for the Study of Diabetes 2, 4
- Transition to subcutaneous insulin using a basal-bolus regimen once the patient is stable, with administration of basal insulin 2-4 hours before discontinuing the insulin infusion, according to the American Association of Clinical Endocrinologists 5
Monitoring and Adjustments
- Monitor serum sodium, potassium, glucose, and osmolality every 2-4 hours initially, as recommended by the American Diabetes Association 1
Special Considerations
- In critically ill patients, maintain glucose levels between 140-180 mg/dL rather than more intensive control to reduce the risk of hypoglycemia, according to the Society of Critical Care Medicine 6
- For patients with cardiac or renal disease, careful monitoring of volume status is essential to prevent fluid overload, as suggested by the American Heart Association 7
Transition of Care and Follow-up
- Develop a structured discharge plan that includes diabetes education, medication reconciliation, and scheduled follow-up, according to the American Diabetes Association 5
- Consider endocrinology consultation for complex cases or patients with recurrent episodes, as recommended by the Endocrine Society 3
Pitfalls to Avoid
- Avoid using sliding scale insulin as the sole regimen as it is reactive rather than proactive and associated with poor glycemic control, according to the American Diabetes Association 8
- Monitor for hypoglycemia, especially during transition from intravenous to subcutaneous insulin, as suggested by the American Association of Clinical Endocrinologists 7